Transgene（TNG）株式概要
バイオテクノロジー企業であるTransgene SAは、フランスでがん治療用の治療ワクチンとオンコリティックウイルスの設計・開発を行っている。 詳細
TNG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Transgene SA 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | €0.83 |
| 52週高値 | €1.50 |
| 52週安値 | €0.58 |
| ベータ | 0.73 |
| 1ヶ月の変化 | 10.08% |
| 3ヶ月変化 | 0.97% |
| 1年変化 | 36.07% |
| 3年間の変化 | -52.89% |
| 5年間の変化 | -72.65% |
| IPOからの変化 | -98.16% |
最新ニュース
ナラティブの更新 • Apr 23
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.ナラティブの更新 • Apr 09
TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.ナラティブの更新 • Mar 25
TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).Recent updates
ナラティブの更新 • Apr 23
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.ナラティブの更新 • Apr 09
TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.ナラティブの更新 • Mar 25
TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).ナラティブの更新 • Mar 11
TNG: Phase I Head And Neck Vaccine Data Will Support Future Repricing
Analysts have maintained their price target for Transgene at €1.10, reflecting largely stable assumptions on the discount rate, revenue trends, margins, and future P/E expectations. What's in the News Transgene released a preprint on medRxiv with a comprehensive analysis of clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine.ナラティブの更新 • Feb 24
TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have reduced their price target for Transgene to €1.10 from €2.00, reflecting updated assumptions that include a higher discount rate, lower revenue growth expectations, improved profit margin and a lower future P/E multiple. What's in the News Transgene released a preprint on medRxiv detailing clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine for operable head and neck cancers (medRxiv preprint).
ナラティブの更新 • Feb 10
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target on Transgene slightly, reflecting updated assumptions for a discount rate, revenue growth of 33.57% and a forward P/E of 27.97x, while keeping fair value at €1.10. This suggests a more finely tuned view of the company’s risk and earnings profile rather than a major shift in outlook.ナラティブの更新 • Jan 26
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target for Transgene, citing updated assumptions on discount rate, revenue growth, profit margin and a lower future P/E multiple as key drivers of the change in valuation. The new target is presented in line with a fair value estimate of €1.10 per share.ナラティブの更新 • Jan 12
TNG: Clinical Progress And Capital Raise Will Support Future Upside
Analysts have adjusted their price target for Transgene, citing updated assumptions that keep fair value at €1.10 while reflecting different views on revenue growth, profit margins, and a higher future P/E multiple. What's in the News Preprint publication on medRxiv shares clinical and translational data from the Phase I part of Transgene's randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine, with the manuscript also submitted to a peer reviewed journal for evaluation (Product related announcement).ナラティブの更新 • Dec 14
TNG: Pipeline Progress And Stronger Balance Sheet Will Drive Future Upside
Analysts have moderately reduced their price target on Transgene, cutting fair value by about 20 percent to approximately 1.10 euros. They have incorporated slower expected revenue growth, a higher discount rate, and a more balanced, though significantly improved, long term profit margin outlook into their models.分析記事 • May 27
Is Transgene (EPA:TNG) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
新しいナラティブ • Apr 07
TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines
Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.分析記事 • Jun 15
Is Transgene (EPA:TNG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Mar 21
Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
One thing we could say about the analysts on Transgene SA ( EPA:TNG ) - they aren't optimistic, having just made a...分析記事 • Mar 19
Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Transgene SA ( EPA:TNG ) released its full-year result to the market. The early...分析記事 • Mar 18
Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 24
Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Apr 16
Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Mar 12
What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?
Every investor in Transgene SA ( EPA:TNG ) should be aware of the most powerful shareholder groups. Insiders often own...株主還元
| TNG | FR Biotechs | FR 市場 | |
|---|---|---|---|
| 7D | -1.1% | 3.4% | 2.0% |
| 1Y | 36.1% | 344.2% | 1.3% |
業界別リターン: TNG過去 1 年間で344.2 % の収益を上げたFrench Biotechs業界を下回りました。
リターン対市場: TNG過去 1 年間で1.3 % の収益を上げたFrench市場を上回りました。
価格変動
| TNG volatility | |
|---|---|
| TNG Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in FR Market | 10.7% |
| 10% least volatile stocks in FR Market | 2.9% |
安定した株価: TNG 、 French市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: TNGの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1979 | 145 | Alessandro Riva | www.transgene.fr |
バイオテクノロジー企業であるTransgene SAは、フランスでがん治療用ワクチンとオンコリティックウイルスの設計・開発を行っている。トランスジーン社は、卵巣癌と頭頸部癌の治療薬として第II相臨床試験中の治療用ワクチンTG4050、ヒトパピローマウイルス（HPV16）陽性癌の治療薬として第II相臨床試験中の治療用ワクチンTG4001の開発に携わっている；消化管腺がんを含む固形がんの治療薬として第I/IIa相臨床試験中の癌溶解性ウイルスTG6002、固形がんの治療薬として第I/II相臨床試験中の癌溶解性ウイルスBT-001。また、非小細胞肺がん治療薬としてTG6050を開発し、第1相臨床試験中であり、固形がん治療薬としてオンコリティックウイルスPexa-Vecを開発している。アストラゼネカ、メルクKGaA、ファイザー、NECと戦略的提携契約を、SillaJen、Ascend BioPharmaceutical、Valnevaとライセンス契約を、Merck & Co、Sanofi、BioInventと契約を結んでいる。同社は1979年に設立され、フランスのイルキルヒ・グラフェンシュタデンに本社を置いている。トランスジーンSAはTSGH SASの子会社である。
Transgene SA 基礎のまとめ
| TNG 基礎統計学 | |
|---|---|
| 時価総額 | €227.32m |
| 収益（TTM） | -€37.52m |
| 売上高(TTM) | €7.21m |
31.5x
P/Sレシオ-6.1x
PER（株価収益率TNG は割高か？
公正価値と評価分析を参照収益と収入
| TNG 損益計算書（TTM） | |
|---|---|
| 収益 | €7.21m |
| 売上原価 | €33.90m |
| 売上総利益 | -€26.69m |
| その他の費用 | €10.84m |
| 収益 | -€37.52m |
直近の収益報告
Dec 31, 2025
次回決算日
Sep 24, 2026
| 一株当たり利益（EPS） | -0.14 |
| グロス・マージン | -370.12% |
| 純利益率 | -520.44% |
| 有利子負債／自己資本比率 | 1.7% |
TNG の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 10:20 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Transgene SA 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |
| Martial Descoutures | ODDO BHF Corporate & Markets |